[1] Chen W, Zheng R, Baade P D, et al. Cancer Statistics in China, 2015. CA- CANCER J CLIN, 2016,66:115-132. [2] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018,391:1023-1075. [3] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版). 临床肝胆病杂志, 2017,33:1419-1431. [4] Moon A M, Weiss N S, Beste L A, et al. No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis. Gastroenterology, 2018,155:1128. [5] Heimbach JK, Kulik LM, Finn RS, et al. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 2018,67:358-380. [6] Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol, 2018,69:182-236. |